Bridge Biotherapeutics, Inc. (KOSDAQ:288330)

Bridge Biotherapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4,773	5,737	14,183	7,942	8,200	20,943
Short-Term Investments	6,620	9,940	6,000	39,500	29,000	37,000
Trading Asset Securities	6,531	6,086	-	3,852	5,928	-
Cash & Short-Term Investments	17,924	21,763	20,183	51,295	43,128	57,943
Cash Growth	24.21%	7.83%	-60.65%	18.94%	-25.57%	-16.21%
Accounts Receivable	-	1.15	-	-	-	572.25
Other Receivables	214.45	332.53	647.21	904.91	365.75	1,171
Receivables	214.45	633.68	647.21	904.91	365.75	1,743
Prepaid Expenses	95.09	159.03	217.98	274.3	305.32	313.24
Other Current Assets	924.44	804.53	683.24	2,483	627.33	304.74
Total Current Assets	19,158	23,360	21,731	54,957	44,426	60,304
Property, Plant & Equipment	2,662	3,037	4,287	3,784	664.25	829.58
Long-Term Investments	1,049	953.54	890.53	470.01	94.06	0
Goodwill	2,367	2,367	2,888	-	-	-
Other Intangible Assets	2,865	2,875	2,777	131.89	179.22	223.78
Long-Term Deferred Charges	89.12	85.24	85.24	-	-	-
Other Long-Term Assets	800.6	813.8	1,564	2,112	1,293	2,153
Total Assets	28,991	33,492	34,222	61,455	46,657	63,510
Accrued Expenses	170.2	165.05	330.51	142.66	119.58	105.07
Current Portion of Leases	1,131	1,192	1,043	993.06	172.93	168.14
Current Unearned Revenue	-	-	-	-	1,076	-
Other Current Liabilities	2,223	2,518	9,002	6,359	2,188	782.26
Total Current Liabilities	3,524	3,875	10,375	7,494	3,556	1,055
Long-Term Leases	1,198	1,434	2,504	2,016	53.63	226.56
Long-Term Unearned Revenue	-	-	-	-	-	3,000
Long-Term Deferred Tax Liabilities	532.97	532.97	532.97	-	-	-
Other Long-Term Liabilities	87.19	86.38	83.22	80.17	0	-0
Total Liabilities	5,342	5,928	13,496	9,590	3,610	4,282
Common Stock	26,081	25,206	11,334	9,948	9,854	9,591
Additional Paid-In Capital	137,153	136,432	122,612	115,998	71,820	65,537
Retained Earnings	-154,357	-149,473	-129,718	-87,397	-45,697	-19,419
Treasury Stock	-	-10.34	-	-	-	-
Comprehensive Income & Other	13,484	13,532	13,269	10,945	7,071	3,519
Total Common Equity	22,362	25,686	17,497	49,494	43,047	59,228
Minority Interest	1,277	1,319	1,349	-	-	-
Shareholders' Equity	23,648	27,565	20,726	51,865	43,047	59,228
Total Liabilities & Equity	28,991	33,492	34,222	61,455	46,657	63,510
Total Debt	2,329	2,625	3,547	3,009	226.56	394.69
Net Cash (Debt)	15,595	19,138	16,636	48,286	42,901	57,548
Net Cash Growth	40.78%	15.04%	-65.55%	12.55%	-25.45%	-16.59%
Net Cash Per Share	347.17	470.22	554.50	2028.30	1830.30	2517.32
Filing Date Shares Outstanding	50.87	50.41	27.2	23.88	23.65	23.02
Total Common Shares Outstanding	50.87	50.41	27.2	23.88	23.65	23.02
Working Capital	15,634	19,486	11,356	47,462	40,870	59,249
Book Value Per Share	439.61	509.53	643.25	2073.00	1820.27	2573.19
Tangible Book Value	17,130	20,444	11,832	49,363	42,868	59,004
Tangible Book Value Per Share	336.75	405.55	434.99	2067.48	1812.69	2563.46
Machinery	1,039	1,113	1,173	929.29	724.31	558.1
Construction In Progress	-	-	-	234.4	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.